Global Human Vaccine Contract Manufacturing Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our latest research, the global Human Vaccine Contract Manufacturing market size will reach USD 14070 million in 2031, growing at a CAGR of 10.8% over the analysis period.
The vaccine contract manufacturing sector pertains to the domain where pharmaceutical firms enlist the services of external contract manufacturing entities for the production of vaccines. These contract manufacturing organizations (CMOs) possess the requisite infrastructure, specialized know-how, and dedicated facilities to manufacture vaccines on behalf of the original developers. Contract manufacturers specializing in human use applications are well-equipped to meet the stringent regulatory requirements and quality standards governing vaccine production for human use.
Market CAGR for vaccine contract manufacturing is being driven by the rising vaccination rates worldwide. In the ever-evolving landscape of governmental and healthcare endeavors aimed at bolstering immunization coverage against the backdrop of infectious maladies, a pressing imperative emerges—a dire necessity for the expansion of vaccine production capacity. Within this exigent milieu, contract manufacturers emerge as veritable linchpins, wielding their prowess in the domain of vaccine production to furnish a panacea of flexible and scalable manufacturing solutions. Endowed with specialized facilities and unwavering fidelity to regulatory strictures, these entities furnish pharmaceutical behemoths with the instrumental means to orchestrate a seamless augmentation of vaccine production capabilities. The harrowing specter of the COVID-19 pandemic has served to magnify the imperative of fortifying vaccine manufacturing prowess, propelling a surge in investments geared towards the fecundation of vaccine development and production endeavors. As the apogee of vaccination rates is charted across the global expanse, the clamor for the services rendered by vaccine contract manufacturers is poised to ascend to vertiginous heights, heralding an epoch of unprecedented market growth. Enmeshed within the tapestry of the Vaccine Contract Manufacturing Market are the sinews of global health exigencies, wherein the specter of infectious disease outbreaks and the omnipresent shadow of pandemics serve as vanguards propelling the market's ascension. The burgeoning ubiquity of infectious pathogens, intertwined with the looming specter of bioterrorism, accentuates the exigency of vaccines as sentinels of public health. In this crucible of exigency, contract manufacturers emerge as valiant custodians, orchestrating a symphony of vaccine manufacturing prowess to assuage the tremors of global health crises.
This report is a detailed and comprehensive analysis for global Human Vaccine Contract Manufacturing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Vaccine Contract Manufacturing market size and forecasts, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Vaccine Contract Manufacturing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Vaccine Contract Manufacturing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc., PRA Health Sciences, ICON plc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Human Vaccine Contract Manufacturing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Human Vaccine Contract Manufacturing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Human Vaccine Contract Manufacturing, with revenue, gross margin, and global market share of Human Vaccine Contract Manufacturing from 2020 to 2025.
Chapter 3, the Human Vaccine Contract Manufacturing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Human Vaccine Contract Manufacturing market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human Vaccine Contract Manufacturing.
Chapter 13, to describe Human Vaccine Contract Manufacturing research findings and conclusion.
The vaccine contract manufacturing sector pertains to the domain where pharmaceutical firms enlist the services of external contract manufacturing entities for the production of vaccines. These contract manufacturing organizations (CMOs) possess the requisite infrastructure, specialized know-how, and dedicated facilities to manufacture vaccines on behalf of the original developers. Contract manufacturers specializing in human use applications are well-equipped to meet the stringent regulatory requirements and quality standards governing vaccine production for human use.
Market CAGR for vaccine contract manufacturing is being driven by the rising vaccination rates worldwide. In the ever-evolving landscape of governmental and healthcare endeavors aimed at bolstering immunization coverage against the backdrop of infectious maladies, a pressing imperative emerges—a dire necessity for the expansion of vaccine production capacity. Within this exigent milieu, contract manufacturers emerge as veritable linchpins, wielding their prowess in the domain of vaccine production to furnish a panacea of flexible and scalable manufacturing solutions. Endowed with specialized facilities and unwavering fidelity to regulatory strictures, these entities furnish pharmaceutical behemoths with the instrumental means to orchestrate a seamless augmentation of vaccine production capabilities. The harrowing specter of the COVID-19 pandemic has served to magnify the imperative of fortifying vaccine manufacturing prowess, propelling a surge in investments geared towards the fecundation of vaccine development and production endeavors. As the apogee of vaccination rates is charted across the global expanse, the clamor for the services rendered by vaccine contract manufacturers is poised to ascend to vertiginous heights, heralding an epoch of unprecedented market growth. Enmeshed within the tapestry of the Vaccine Contract Manufacturing Market are the sinews of global health exigencies, wherein the specter of infectious disease outbreaks and the omnipresent shadow of pandemics serve as vanguards propelling the market's ascension. The burgeoning ubiquity of infectious pathogens, intertwined with the looming specter of bioterrorism, accentuates the exigency of vaccines as sentinels of public health. In this crucible of exigency, contract manufacturers emerge as valiant custodians, orchestrating a symphony of vaccine manufacturing prowess to assuage the tremors of global health crises.
This report is a detailed and comprehensive analysis for global Human Vaccine Contract Manufacturing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Vaccine Contract Manufacturing market size and forecasts, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Human Vaccine Contract Manufacturing market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Vaccine Contract Manufacturing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Vaccine Contract Manufacturing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc., PRA Health Sciences, ICON plc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Human Vaccine Contract Manufacturing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Attenuated
- Inactivated
- Subunit-based
- Toxoid-based
- DNA-based
- Downstream
- Upstream
- Lonza
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Ajinomoto Althea, Inc.
- Merck KgaA
- Cytovance Biologics
- Catalent, Inc.
- IDT Biologika GmbH
- Albany Molecular Research, Inc.
- PRA Health Sciences
- ICON plc.
- Pharmaceutical Product Development, LLC
- Cobra Bio
- Paragon Bioservices, Inc.
- Emergent BioSolutions Inc.
- CSL Limited
- BioNTech SE
- Wuxi Biologics
- Samsung Biologics
- Boehringer Ingelheim
- Novavax, Inc.
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Human Vaccine Contract Manufacturing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Human Vaccine Contract Manufacturing, with revenue, gross margin, and global market share of Human Vaccine Contract Manufacturing from 2020 to 2025.
Chapter 3, the Human Vaccine Contract Manufacturing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Human Vaccine Contract Manufacturing market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human Vaccine Contract Manufacturing.
Chapter 13, to describe Human Vaccine Contract Manufacturing research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Human Vaccine Contract Manufacturing by Type
1.3.1 Overview: Global Human Vaccine Contract Manufacturing Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Type in 2024
1.3.3 Attenuated
1.3.4 Inactivated
1.3.5 Subunit-based
1.3.6 Toxoid-based
1.3.7 DNA-based
1.4 Global Human Vaccine Contract Manufacturing Market by Application
1.4.1 Overview: Global Human Vaccine Contract Manufacturing Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Downstream
1.4.3 Upstream
1.5 Global Human Vaccine Contract Manufacturing Market Size & Forecast
1.6 Global Human Vaccine Contract Manufacturing Market Size and Forecast by Region
1.6.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Human Vaccine Contract Manufacturing Market Size by Region, (2020-2031)
1.6.3 North America Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.4 Europe Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.6 South America Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Human Vaccine Contract Manufacturing Product and Solutions
2.1.4 Lonza Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
2.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Details
2.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Major Business
2.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments and Future Plans
2.3 Ajinomoto Althea, Inc.
2.3.1 Ajinomoto Althea, Inc. Details
2.3.2 Ajinomoto Althea, Inc. Major Business
2.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Ajinomoto Althea, Inc. Recent Developments and Future Plans
2.4 Merck KgaA
2.4.1 Merck KgaA Details
2.4.2 Merck KgaA Major Business
2.4.3 Merck KgaA Human Vaccine Contract Manufacturing Product and Solutions
2.4.4 Merck KgaA Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Merck KgaA Recent Developments and Future Plans
2.5 Cytovance Biologics
2.5.1 Cytovance Biologics Details
2.5.2 Cytovance Biologics Major Business
2.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Cytovance Biologics Recent Developments and Future Plans
2.6 Catalent, Inc.
2.6.1 Catalent, Inc. Details
2.6.2 Catalent, Inc. Major Business
2.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Catalent, Inc. Recent Developments and Future Plans
2.7 IDT Biologika GmbH
2.7.1 IDT Biologika GmbH Details
2.7.2 IDT Biologika GmbH Major Business
2.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product and Solutions
2.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 IDT Biologika GmbH Recent Developments and Future Plans
2.8 Albany Molecular Research, Inc.
2.8.1 Albany Molecular Research, Inc. Details
2.8.2 Albany Molecular Research, Inc. Major Business
2.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Albany Molecular Research, Inc. Recent Developments and Future Plans
2.9 PRA Health Sciences
2.9.1 PRA Health Sciences Details
2.9.2 PRA Health Sciences Major Business
2.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Product and Solutions
2.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 PRA Health Sciences Recent Developments and Future Plans
2.10 ICON plc.
2.10.1 ICON plc. Details
2.10.2 ICON plc. Major Business
2.10.3 ICON plc. Human Vaccine Contract Manufacturing Product and Solutions
2.10.4 ICON plc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 ICON plc. Recent Developments and Future Plans
2.11 Pharmaceutical Product Development, LLC
2.11.1 Pharmaceutical Product Development, LLC Details
2.11.2 Pharmaceutical Product Development, LLC Major Business
2.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product and Solutions
2.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Pharmaceutical Product Development, LLC Recent Developments and Future Plans
2.12 Cobra Bio
2.12.1 Cobra Bio Details
2.12.2 Cobra Bio Major Business
2.12.3 Cobra Bio Human Vaccine Contract Manufacturing Product and Solutions
2.12.4 Cobra Bio Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Cobra Bio Recent Developments and Future Plans
2.13 Paragon Bioservices, Inc.
2.13.1 Paragon Bioservices, Inc. Details
2.13.2 Paragon Bioservices, Inc. Major Business
2.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Paragon Bioservices, Inc. Recent Developments and Future Plans
2.14 Emergent BioSolutions Inc.
2.14.1 Emergent BioSolutions Inc. Details
2.14.2 Emergent BioSolutions Inc. Major Business
2.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Emergent BioSolutions Inc. Recent Developments and Future Plans
2.15 CSL Limited
2.15.1 CSL Limited Details
2.15.2 CSL Limited Major Business
2.15.3 CSL Limited Human Vaccine Contract Manufacturing Product and Solutions
2.15.4 CSL Limited Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 CSL Limited Recent Developments and Future Plans
2.16 BioNTech SE
2.16.1 BioNTech SE Details
2.16.2 BioNTech SE Major Business
2.16.3 BioNTech SE Human Vaccine Contract Manufacturing Product and Solutions
2.16.4 BioNTech SE Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 BioNTech SE Recent Developments and Future Plans
2.17 Wuxi Biologics
2.17.1 Wuxi Biologics Details
2.17.2 Wuxi Biologics Major Business
2.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Wuxi Biologics Recent Developments and Future Plans
2.18 Samsung Biologics
2.18.1 Samsung Biologics Details
2.18.2 Samsung Biologics Major Business
2.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Samsung Biologics Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product and Solutions
2.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
2.20 Novavax, Inc.
2.20.1 Novavax, Inc. Details
2.20.2 Novavax, Inc. Major Business
2.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 Novavax, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Human Vaccine Contract Manufacturing Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Human Vaccine Contract Manufacturing by Company Revenue
3.2.2 Top 3 Human Vaccine Contract Manufacturing Players Market Share in 2024
3.2.3 Top 6 Human Vaccine Contract Manufacturing Players Market Share in 2024
3.3 Human Vaccine Contract Manufacturing Market: Overall Company Footprint Analysis
3.3.1 Human Vaccine Contract Manufacturing Market: Region Footprint
3.3.2 Human Vaccine Contract Manufacturing Market: Company Product Type Footprint
3.3.3 Human Vaccine Contract Manufacturing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Human Vaccine Contract Manufacturing Consumption Value and Market Share by Type (2020-2025)
4.2 Global Human Vaccine Contract Manufacturing Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2025)
5.2 Global Human Vaccine Contract Manufacturing Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
6.2 North America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
6.3 North America Human Vaccine Contract Manufacturing Market Size by Country
6.3.1 North America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
6.3.2 United States Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
6.3.3 Canada Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
6.3.4 Mexico Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
7.2 Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
7.3 Europe Human Vaccine Contract Manufacturing Market Size by Country
7.3.1 Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
7.3.2 Germany Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.3 France Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.5 Russia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.6 Italy Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region
8.3.1 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2031)
8.3.2 China Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.3 Japan Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.4 South Korea Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.5 India Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.7 Australia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
9.2 South America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
9.3 South America Human Vaccine Contract Manufacturing Market Size by Country
9.3.1 South America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
9.3.2 Brazil Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
9.3.3 Argentina Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country
10.3.1 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
10.3.2 Turkey Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10.3.4 UAE Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Human Vaccine Contract Manufacturing Market Drivers
11.2 Human Vaccine Contract Manufacturing Market Restraints
11.3 Human Vaccine Contract Manufacturing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Human Vaccine Contract Manufacturing Industry Chain
12.2 Human Vaccine Contract Manufacturing Upstream Analysis
12.3 Human Vaccine Contract Manufacturing Midstream Analysis
12.4 Human Vaccine Contract Manufacturing Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Human Vaccine Contract Manufacturing by Type
1.3.1 Overview: Global Human Vaccine Contract Manufacturing Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Type in 2024
1.3.3 Attenuated
1.3.4 Inactivated
1.3.5 Subunit-based
1.3.6 Toxoid-based
1.3.7 DNA-based
1.4 Global Human Vaccine Contract Manufacturing Market by Application
1.4.1 Overview: Global Human Vaccine Contract Manufacturing Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Downstream
1.4.3 Upstream
1.5 Global Human Vaccine Contract Manufacturing Market Size & Forecast
1.6 Global Human Vaccine Contract Manufacturing Market Size and Forecast by Region
1.6.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Human Vaccine Contract Manufacturing Market Size by Region, (2020-2031)
1.6.3 North America Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.4 Europe Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.6 South America Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Human Vaccine Contract Manufacturing Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Human Vaccine Contract Manufacturing Product and Solutions
2.1.4 Lonza Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
2.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Details
2.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Major Business
2.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments and Future Plans
2.3 Ajinomoto Althea, Inc.
2.3.1 Ajinomoto Althea, Inc. Details
2.3.2 Ajinomoto Althea, Inc. Major Business
2.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Ajinomoto Althea, Inc. Recent Developments and Future Plans
2.4 Merck KgaA
2.4.1 Merck KgaA Details
2.4.2 Merck KgaA Major Business
2.4.3 Merck KgaA Human Vaccine Contract Manufacturing Product and Solutions
2.4.4 Merck KgaA Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Merck KgaA Recent Developments and Future Plans
2.5 Cytovance Biologics
2.5.1 Cytovance Biologics Details
2.5.2 Cytovance Biologics Major Business
2.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Cytovance Biologics Recent Developments and Future Plans
2.6 Catalent, Inc.
2.6.1 Catalent, Inc. Details
2.6.2 Catalent, Inc. Major Business
2.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Catalent, Inc. Recent Developments and Future Plans
2.7 IDT Biologika GmbH
2.7.1 IDT Biologika GmbH Details
2.7.2 IDT Biologika GmbH Major Business
2.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product and Solutions
2.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 IDT Biologika GmbH Recent Developments and Future Plans
2.8 Albany Molecular Research, Inc.
2.8.1 Albany Molecular Research, Inc. Details
2.8.2 Albany Molecular Research, Inc. Major Business
2.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Albany Molecular Research, Inc. Recent Developments and Future Plans
2.9 PRA Health Sciences
2.9.1 PRA Health Sciences Details
2.9.2 PRA Health Sciences Major Business
2.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Product and Solutions
2.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 PRA Health Sciences Recent Developments and Future Plans
2.10 ICON plc.
2.10.1 ICON plc. Details
2.10.2 ICON plc. Major Business
2.10.3 ICON plc. Human Vaccine Contract Manufacturing Product and Solutions
2.10.4 ICON plc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 ICON plc. Recent Developments and Future Plans
2.11 Pharmaceutical Product Development, LLC
2.11.1 Pharmaceutical Product Development, LLC Details
2.11.2 Pharmaceutical Product Development, LLC Major Business
2.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product and Solutions
2.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Pharmaceutical Product Development, LLC Recent Developments and Future Plans
2.12 Cobra Bio
2.12.1 Cobra Bio Details
2.12.2 Cobra Bio Major Business
2.12.3 Cobra Bio Human Vaccine Contract Manufacturing Product and Solutions
2.12.4 Cobra Bio Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Cobra Bio Recent Developments and Future Plans
2.13 Paragon Bioservices, Inc.
2.13.1 Paragon Bioservices, Inc. Details
2.13.2 Paragon Bioservices, Inc. Major Business
2.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Paragon Bioservices, Inc. Recent Developments and Future Plans
2.14 Emergent BioSolutions Inc.
2.14.1 Emergent BioSolutions Inc. Details
2.14.2 Emergent BioSolutions Inc. Major Business
2.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Emergent BioSolutions Inc. Recent Developments and Future Plans
2.15 CSL Limited
2.15.1 CSL Limited Details
2.15.2 CSL Limited Major Business
2.15.3 CSL Limited Human Vaccine Contract Manufacturing Product and Solutions
2.15.4 CSL Limited Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 CSL Limited Recent Developments and Future Plans
2.16 BioNTech SE
2.16.1 BioNTech SE Details
2.16.2 BioNTech SE Major Business
2.16.3 BioNTech SE Human Vaccine Contract Manufacturing Product and Solutions
2.16.4 BioNTech SE Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 BioNTech SE Recent Developments and Future Plans
2.17 Wuxi Biologics
2.17.1 Wuxi Biologics Details
2.17.2 Wuxi Biologics Major Business
2.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Wuxi Biologics Recent Developments and Future Plans
2.18 Samsung Biologics
2.18.1 Samsung Biologics Details
2.18.2 Samsung Biologics Major Business
2.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Product and Solutions
2.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Samsung Biologics Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product and Solutions
2.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
2.20 Novavax, Inc.
2.20.1 Novavax, Inc. Details
2.20.2 Novavax, Inc. Major Business
2.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Product and Solutions
2.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 Novavax, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Human Vaccine Contract Manufacturing Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Human Vaccine Contract Manufacturing by Company Revenue
3.2.2 Top 3 Human Vaccine Contract Manufacturing Players Market Share in 2024
3.2.3 Top 6 Human Vaccine Contract Manufacturing Players Market Share in 2024
3.3 Human Vaccine Contract Manufacturing Market: Overall Company Footprint Analysis
3.3.1 Human Vaccine Contract Manufacturing Market: Region Footprint
3.3.2 Human Vaccine Contract Manufacturing Market: Company Product Type Footprint
3.3.3 Human Vaccine Contract Manufacturing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Human Vaccine Contract Manufacturing Consumption Value and Market Share by Type (2020-2025)
4.2 Global Human Vaccine Contract Manufacturing Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2025)
5.2 Global Human Vaccine Contract Manufacturing Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
6.2 North America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
6.3 North America Human Vaccine Contract Manufacturing Market Size by Country
6.3.1 North America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
6.3.2 United States Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
6.3.3 Canada Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
6.3.4 Mexico Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
7.2 Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
7.3 Europe Human Vaccine Contract Manufacturing Market Size by Country
7.3.1 Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
7.3.2 Germany Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.3 France Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.5 Russia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
7.3.6 Italy Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region
8.3.1 Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2031)
8.3.2 China Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.3 Japan Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.4 South Korea Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.5 India Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
8.3.7 Australia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
9.2 South America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
9.3 South America Human Vaccine Contract Manufacturing Market Size by Country
9.3.1 South America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
9.3.2 Brazil Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
9.3.3 Argentina Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country
10.3.1 Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2031)
10.3.2 Turkey Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
10.3.4 UAE Human Vaccine Contract Manufacturing Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Human Vaccine Contract Manufacturing Market Drivers
11.2 Human Vaccine Contract Manufacturing Market Restraints
11.3 Human Vaccine Contract Manufacturing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Human Vaccine Contract Manufacturing Industry Chain
12.2 Human Vaccine Contract Manufacturing Upstream Analysis
12.3 Human Vaccine Contract Manufacturing Midstream Analysis
12.4 Human Vaccine Contract Manufacturing Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Human Vaccine Contract Manufacturing Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Human Vaccine Contract Manufacturing Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Human Vaccine Contract Manufacturing Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Lonza Company Information, Head Office, and Major Competitors
Table 6. Lonza Major Business
Table 7. Lonza Human Vaccine Contract Manufacturing Product and Solutions
Table 8. Lonza Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Lonza Recent Developments and Future Plans
Table 10. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information, Head Office, and Major Competitors
Table 11. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Major Business
Table 12. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 13. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments and Future Plans
Table 15. Ajinomoto Althea, Inc. Company Information, Head Office, and Major Competitors
Table 16. Ajinomoto Althea, Inc. Major Business
Table 17. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 18. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Merck KgaA Company Information, Head Office, and Major Competitors
Table 20. Merck KgaA Major Business
Table 21. Merck KgaA Human Vaccine Contract Manufacturing Product and Solutions
Table 22. Merck KgaA Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Merck KgaA Recent Developments and Future Plans
Table 24. Cytovance Biologics Company Information, Head Office, and Major Competitors
Table 25. Cytovance Biologics Major Business
Table 26. Cytovance Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 27. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Cytovance Biologics Recent Developments and Future Plans
Table 29. Catalent, Inc. Company Information, Head Office, and Major Competitors
Table 30. Catalent, Inc. Major Business
Table 31. Catalent, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 32. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Catalent, Inc. Recent Developments and Future Plans
Table 34. IDT Biologika GmbH Company Information, Head Office, and Major Competitors
Table 35. IDT Biologika GmbH Major Business
Table 36. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product and Solutions
Table 37. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. IDT Biologika GmbH Recent Developments and Future Plans
Table 39. Albany Molecular Research, Inc. Company Information, Head Office, and Major Competitors
Table 40. Albany Molecular Research, Inc. Major Business
Table 41. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 42. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Albany Molecular Research, Inc. Recent Developments and Future Plans
Table 44. PRA Health Sciences Company Information, Head Office, and Major Competitors
Table 45. PRA Health Sciences Major Business
Table 46. PRA Health Sciences Human Vaccine Contract Manufacturing Product and Solutions
Table 47. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. PRA Health Sciences Recent Developments and Future Plans
Table 49. ICON plc. Company Information, Head Office, and Major Competitors
Table 50. ICON plc. Major Business
Table 51. ICON plc. Human Vaccine Contract Manufacturing Product and Solutions
Table 52. ICON plc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. ICON plc. Recent Developments and Future Plans
Table 54. Pharmaceutical Product Development, LLC Company Information, Head Office, and Major Competitors
Table 55. Pharmaceutical Product Development, LLC Major Business
Table 56. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product and Solutions
Table 57. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Pharmaceutical Product Development, LLC Recent Developments and Future Plans
Table 59. Cobra Bio Company Information, Head Office, and Major Competitors
Table 60. Cobra Bio Major Business
Table 61. Cobra Bio Human Vaccine Contract Manufacturing Product and Solutions
Table 62. Cobra Bio Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Cobra Bio Recent Developments and Future Plans
Table 64. Paragon Bioservices, Inc. Company Information, Head Office, and Major Competitors
Table 65. Paragon Bioservices, Inc. Major Business
Table 66. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 67. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Paragon Bioservices, Inc. Recent Developments and Future Plans
Table 69. Emergent BioSolutions Inc. Company Information, Head Office, and Major Competitors
Table 70. Emergent BioSolutions Inc. Major Business
Table 71. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 72. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Emergent BioSolutions Inc. Recent Developments and Future Plans
Table 74. CSL Limited Company Information, Head Office, and Major Competitors
Table 75. CSL Limited Major Business
Table 76. CSL Limited Human Vaccine Contract Manufacturing Product and Solutions
Table 77. CSL Limited Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. CSL Limited Recent Developments and Future Plans
Table 79. BioNTech SE Company Information, Head Office, and Major Competitors
Table 80. BioNTech SE Major Business
Table 81. BioNTech SE Human Vaccine Contract Manufacturing Product and Solutions
Table 82. BioNTech SE Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. BioNTech SE Recent Developments and Future Plans
Table 84. Wuxi Biologics Company Information, Head Office, and Major Competitors
Table 85. Wuxi Biologics Major Business
Table 86. Wuxi Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 87. Wuxi Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Wuxi Biologics Recent Developments and Future Plans
Table 89. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 90. Samsung Biologics Major Business
Table 91. Samsung Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 92. Samsung Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Samsung Biologics Recent Developments and Future Plans
Table 94. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 95. Boehringer Ingelheim Major Business
Table 96. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product and Solutions
Table 97. Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Boehringer Ingelheim Recent Developments and Future Plans
Table 99. Novavax, Inc. Company Information, Head Office, and Major Competitors
Table 100. Novavax, Inc. Major Business
Table 101. Novavax, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 102. Novavax, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. Novavax, Inc. Recent Developments and Future Plans
Table 104. Global Human Vaccine Contract Manufacturing Revenue (USD Million) by Players (2020-2025)
Table 105. Global Human Vaccine Contract Manufacturing Revenue Share by Players (2020-2025)
Table 106. Breakdown of Human Vaccine Contract Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Human Vaccine Contract Manufacturing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 108. Head Office of Key Human Vaccine Contract Manufacturing Players
Table 109. Human Vaccine Contract Manufacturing Market: Company Product Type Footprint
Table 110. Human Vaccine Contract Manufacturing Market: Company Product Application Footprint
Table 111. Human Vaccine Contract Manufacturing New Market Entrants and Barriers to Market Entry
Table 112. Human Vaccine Contract Manufacturing Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Human Vaccine Contract Manufacturing Consumption Value (USD Million) by Type (2020-2025)
Table 114. Global Human Vaccine Contract Manufacturing Consumption Value Share by Type (2020-2025)
Table 115. Global Human Vaccine Contract Manufacturing Consumption Value Forecast by Type (2026-2031)
Table 116. Global Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025)
Table 117. Global Human Vaccine Contract Manufacturing Consumption Value Forecast by Application (2026-2031)
Table 118. North America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 119. North America Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 120. North America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 121. North America Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 122. North America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 125. Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 126. Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 127. Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 128. Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 129. Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 130. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 131. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 132. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 133. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 134. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2025) & (USD Million)
Table 135. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2026-2031) & (USD Million)
Table 136. South America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 137. South America Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 138. South America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 139. South America Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 140. South America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 141. South America Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 142. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 143. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 144. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 145. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 146. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 147. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Global Key Players of Human Vaccine Contract Manufacturing Upstream (Raw Materials)
Table 149. Global Human Vaccine Contract Manufacturing Typical Customers
Table 1. Global Human Vaccine Contract Manufacturing Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Human Vaccine Contract Manufacturing Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Human Vaccine Contract Manufacturing Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Lonza Company Information, Head Office, and Major Competitors
Table 6. Lonza Major Business
Table 7. Lonza Human Vaccine Contract Manufacturing Product and Solutions
Table 8. Lonza Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Lonza Recent Developments and Future Plans
Table 10. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information, Head Office, and Major Competitors
Table 11. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Major Business
Table 12. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 13. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments and Future Plans
Table 15. Ajinomoto Althea, Inc. Company Information, Head Office, and Major Competitors
Table 16. Ajinomoto Althea, Inc. Major Business
Table 17. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 18. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Merck KgaA Company Information, Head Office, and Major Competitors
Table 20. Merck KgaA Major Business
Table 21. Merck KgaA Human Vaccine Contract Manufacturing Product and Solutions
Table 22. Merck KgaA Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Merck KgaA Recent Developments and Future Plans
Table 24. Cytovance Biologics Company Information, Head Office, and Major Competitors
Table 25. Cytovance Biologics Major Business
Table 26. Cytovance Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 27. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Cytovance Biologics Recent Developments and Future Plans
Table 29. Catalent, Inc. Company Information, Head Office, and Major Competitors
Table 30. Catalent, Inc. Major Business
Table 31. Catalent, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 32. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Catalent, Inc. Recent Developments and Future Plans
Table 34. IDT Biologika GmbH Company Information, Head Office, and Major Competitors
Table 35. IDT Biologika GmbH Major Business
Table 36. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product and Solutions
Table 37. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. IDT Biologika GmbH Recent Developments and Future Plans
Table 39. Albany Molecular Research, Inc. Company Information, Head Office, and Major Competitors
Table 40. Albany Molecular Research, Inc. Major Business
Table 41. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 42. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Albany Molecular Research, Inc. Recent Developments and Future Plans
Table 44. PRA Health Sciences Company Information, Head Office, and Major Competitors
Table 45. PRA Health Sciences Major Business
Table 46. PRA Health Sciences Human Vaccine Contract Manufacturing Product and Solutions
Table 47. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. PRA Health Sciences Recent Developments and Future Plans
Table 49. ICON plc. Company Information, Head Office, and Major Competitors
Table 50. ICON plc. Major Business
Table 51. ICON plc. Human Vaccine Contract Manufacturing Product and Solutions
Table 52. ICON plc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. ICON plc. Recent Developments and Future Plans
Table 54. Pharmaceutical Product Development, LLC Company Information, Head Office, and Major Competitors
Table 55. Pharmaceutical Product Development, LLC Major Business
Table 56. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product and Solutions
Table 57. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Pharmaceutical Product Development, LLC Recent Developments and Future Plans
Table 59. Cobra Bio Company Information, Head Office, and Major Competitors
Table 60. Cobra Bio Major Business
Table 61. Cobra Bio Human Vaccine Contract Manufacturing Product and Solutions
Table 62. Cobra Bio Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Cobra Bio Recent Developments and Future Plans
Table 64. Paragon Bioservices, Inc. Company Information, Head Office, and Major Competitors
Table 65. Paragon Bioservices, Inc. Major Business
Table 66. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 67. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Paragon Bioservices, Inc. Recent Developments and Future Plans
Table 69. Emergent BioSolutions Inc. Company Information, Head Office, and Major Competitors
Table 70. Emergent BioSolutions Inc. Major Business
Table 71. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 72. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Emergent BioSolutions Inc. Recent Developments and Future Plans
Table 74. CSL Limited Company Information, Head Office, and Major Competitors
Table 75. CSL Limited Major Business
Table 76. CSL Limited Human Vaccine Contract Manufacturing Product and Solutions
Table 77. CSL Limited Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. CSL Limited Recent Developments and Future Plans
Table 79. BioNTech SE Company Information, Head Office, and Major Competitors
Table 80. BioNTech SE Major Business
Table 81. BioNTech SE Human Vaccine Contract Manufacturing Product and Solutions
Table 82. BioNTech SE Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. BioNTech SE Recent Developments and Future Plans
Table 84. Wuxi Biologics Company Information, Head Office, and Major Competitors
Table 85. Wuxi Biologics Major Business
Table 86. Wuxi Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 87. Wuxi Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Wuxi Biologics Recent Developments and Future Plans
Table 89. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 90. Samsung Biologics Major Business
Table 91. Samsung Biologics Human Vaccine Contract Manufacturing Product and Solutions
Table 92. Samsung Biologics Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Samsung Biologics Recent Developments and Future Plans
Table 94. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 95. Boehringer Ingelheim Major Business
Table 96. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product and Solutions
Table 97. Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Boehringer Ingelheim Recent Developments and Future Plans
Table 99. Novavax, Inc. Company Information, Head Office, and Major Competitors
Table 100. Novavax, Inc. Major Business
Table 101. Novavax, Inc. Human Vaccine Contract Manufacturing Product and Solutions
Table 102. Novavax, Inc. Human Vaccine Contract Manufacturing Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. Novavax, Inc. Recent Developments and Future Plans
Table 104. Global Human Vaccine Contract Manufacturing Revenue (USD Million) by Players (2020-2025)
Table 105. Global Human Vaccine Contract Manufacturing Revenue Share by Players (2020-2025)
Table 106. Breakdown of Human Vaccine Contract Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Human Vaccine Contract Manufacturing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 108. Head Office of Key Human Vaccine Contract Manufacturing Players
Table 109. Human Vaccine Contract Manufacturing Market: Company Product Type Footprint
Table 110. Human Vaccine Contract Manufacturing Market: Company Product Application Footprint
Table 111. Human Vaccine Contract Manufacturing New Market Entrants and Barriers to Market Entry
Table 112. Human Vaccine Contract Manufacturing Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Human Vaccine Contract Manufacturing Consumption Value (USD Million) by Type (2020-2025)
Table 114. Global Human Vaccine Contract Manufacturing Consumption Value Share by Type (2020-2025)
Table 115. Global Human Vaccine Contract Manufacturing Consumption Value Forecast by Type (2026-2031)
Table 116. Global Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025)
Table 117. Global Human Vaccine Contract Manufacturing Consumption Value Forecast by Application (2026-2031)
Table 118. North America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 119. North America Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 120. North America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 121. North America Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 122. North America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 125. Europe Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 126. Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 127. Europe Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 128. Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 129. Europe Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 130. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 131. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 132. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 133. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 134. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2020-2025) & (USD Million)
Table 135. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value by Region (2026-2031) & (USD Million)
Table 136. South America Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 137. South America Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 138. South America Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 139. South America Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 140. South America Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 141. South America Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 142. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2020-2025) & (USD Million)
Table 143. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Type (2026-2031) & (USD Million)
Table 144. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2020-2025) & (USD Million)
Table 145. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Application (2026-2031) & (USD Million)
Table 146. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2020-2025) & (USD Million)
Table 147. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Global Key Players of Human Vaccine Contract Manufacturing Upstream (Raw Materials)
Table 149. Global Human Vaccine Contract Manufacturing Typical Customers
LIST OF FIGURES
Figure 1. Human Vaccine Contract Manufacturing Picture
Figure 2. Global Human Vaccine Contract Manufacturing Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Type in 2024
Figure 4. Attenuated
Figure 5. Inactivated
Figure 6. Subunit-based
Figure 7. Toxoid-based
Figure 8. DNA-based
Figure 9. Global Human Vaccine Contract Manufacturing Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Human Vaccine Contract Manufacturing Consumption Value Market Share by Application in 2024
Figure 11. Downstream Picture
Figure 12. Upstream Picture
Figure 13. Global Human Vaccine Contract Manufacturing Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Human Vaccine Contract Manufacturing Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Human Vaccine Contract Manufacturing Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Region in 2024
Figure 18. North America Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Human Vaccine Contract Manufacturing Revenue Share by Players in 2024
Figure 25. Human Vaccine Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Human Vaccine Contract Manufacturing by Player Revenue in 2024
Figure 27. Top 3 Human Vaccine Contract Manufacturing Players Market Share in 2024
Figure 28. Top 6 Human Vaccine Contract Manufacturing Players Market Share in 2024
Figure 29. Global Human Vaccine Contract Manufacturing Consumption Value Share by Type (2020-2025)
Figure 30. Global Human Vaccine Contract Manufacturing Market Share Forecast by Type (2026-2031)
Figure 31. Global Human Vaccine Contract Manufacturing Consumption Value Share by Application (2020-2025)
Figure 32. Global Human Vaccine Contract Manufacturing Market Share Forecast by Application (2026-2031)
Figure 33. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 43. France Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Region (2020-2031)
Figure 50. China Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 53. India Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 67. Human Vaccine Contract Manufacturing Market Drivers
Figure 68. Human Vaccine Contract Manufacturing Market Restraints
Figure 69. Human Vaccine Contract Manufacturing Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Human Vaccine Contract Manufacturing Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Human Vaccine Contract Manufacturing Picture
Figure 2. Global Human Vaccine Contract Manufacturing Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Type in 2024
Figure 4. Attenuated
Figure 5. Inactivated
Figure 6. Subunit-based
Figure 7. Toxoid-based
Figure 8. DNA-based
Figure 9. Global Human Vaccine Contract Manufacturing Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Human Vaccine Contract Manufacturing Consumption Value Market Share by Application in 2024
Figure 11. Downstream Picture
Figure 12. Upstream Picture
Figure 13. Global Human Vaccine Contract Manufacturing Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Human Vaccine Contract Manufacturing Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Human Vaccine Contract Manufacturing Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Human Vaccine Contract Manufacturing Consumption Value Market Share by Region in 2024
Figure 18. North America Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Human Vaccine Contract Manufacturing Revenue Share by Players in 2024
Figure 25. Human Vaccine Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Human Vaccine Contract Manufacturing by Player Revenue in 2024
Figure 27. Top 3 Human Vaccine Contract Manufacturing Players Market Share in 2024
Figure 28. Top 6 Human Vaccine Contract Manufacturing Players Market Share in 2024
Figure 29. Global Human Vaccine Contract Manufacturing Consumption Value Share by Type (2020-2025)
Figure 30. Global Human Vaccine Contract Manufacturing Market Share Forecast by Type (2026-2031)
Figure 31. Global Human Vaccine Contract Manufacturing Consumption Value Share by Application (2020-2025)
Figure 32. Global Human Vaccine Contract Manufacturing Market Share Forecast by Application (2026-2031)
Figure 33. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 43. France Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Human Vaccine Contract Manufacturing Consumption Value Market Share by Region (2020-2031)
Figure 50. China Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 53. India Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Human Vaccine Contract Manufacturing Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Human Vaccine Contract Manufacturing Consumption Value (2020-2031) & (USD Million)
Figure 67. Human Vaccine Contract Manufacturing Market Drivers
Figure 68. Human Vaccine Contract Manufacturing Market Restraints
Figure 69. Human Vaccine Contract Manufacturing Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Human Vaccine Contract Manufacturing Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
